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OBJECTIVES The present study was undertaken to investigate the relationship over time between exertional
symptoms in heart failure and functional capacity.
BACKGROUND Most clinicians rely on exertional symptoms rather than on exercise testing to assess
functional capacity in heart failure. However, it remains uncertain whether the subjective
symptoms reported by patients provide a reliable index of functional capacity.
METHODS Fifty patients with heart failure underwent serial cardiopulmonary exercise testing and
evaluation of exertional fatigue and dyspnea over a period of one to four years. Exercise testing
was performed using the Naughton treadmill protocol and a MedGraphics metabolic cart.
Fatigue and dyspnea were each scored from 0 to 3 (p 5 none, 1 5 mild, 2 5 moderate, 3 5
severe). A composite symptom score was determined by adding together the fatigue and
dyspnea scores.
RESULTS Patients underwent a total of 185 tests at an average interval of 4.3 months (average
tests/patient 5 3.7). Composite symptom scores noted at the time of exercise testing
correlated significantly with peak exercise minute oxygen consumption (VO2) (r 5 0.47, p ,
0.01). In addition, the change in symptoms scores and change in peak VO2 noted between
the baseline and final exercise test correlated significantly (r 5 0.50, p , 0.01). However,
patients reported few or no symptoms (symptom score #2) 45% of the time when peak VO2
was ,14 ml/min/kg, consistent with a severe functional disability, and 72% of the time when
peak VO2 was 14 to 18 ml/min/kg, consistent with moderate functional disability.
CONCLUSIONS Exertional symptoms reported by patients with heart failure generally correlate with maximal
exercise capacity. However, exertional symptoms frequently underestimate the severity of
functional disability. Cardiopulmonary exercise testing rather than symptoms should be used
to assess functional capacity in heart failure. (J Am Coll Cardiol 1999;33:1943–7) © 1999 by
the American College of Cardiology
Functional disability, or an inability to perform activities
normally, is one of the most common problems experienced
by patients with heart failure (1–3). Therefore, one of the
major goals of heart failure management is to improve
functional capacity. To accomplish this, it is important that
clinicians utilize reliable methods for detecting and moni-
toring the functional capacity of this population.
Most clinicians currently use the clinical history rather
than formal exercise testing to assess and monitor the
functional capacity of patients with heart failure. This
strategy has also recently been recommended by the Amer-
ican Heart Association and American College of Cardiol-
ogy guidelines for the management of heart failure (4).
These guidelines recommend the use of exercise testing only
in potential candidates for heart transplantation and specif-
ically discourage the use of exercise testing as a method of
following clinically stable patients with heart failure.
The relationship between symptoms reported by patients
and functional capacity remains uncertain, however. Func-
tional capacity indicates the ability of a patient to perform
work and is traditionally measured by comparing a patient’s
peak exercise capacity with the exercise capacity of age- and
gender-matched normal control subjects. In contrast, the
symptoms reported by patients reflect their subjective re-
sponse to daily activities. Patients with heart failure often
learn to avoid activities that produce exertional symptoms or
may change the pace of activities to minimize symptoms.
Therefore, the clinical history may provide unreliable infor-
mation about the functional capacity of patients.
The present study was undertaken to further clarify the
relationship over time between exertional symptoms re-
ported by patients with heart failure and their functional
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capacity as measured by maximal cardiopulmonary exercise
testing.
METHODS
Patient population. Studies were performed on 50 sequen-
tial ambulatory patients followed by the Heart Failure and
Heart Transplantation Program at Vanderbilt University
Medical Center. All patients had a history of chronic heart
failure for over six months, and all patients were ambulatory
and receiving digoxin, an angiotensin-converting enzyme
inhibitor and diuretics. Forty-one patients were male and
nine were female. The average age was 51 6 9 years (range
39 to 68 years). The left ventricular ejection fraction
averaged 26 6 10%. Heart failure was attributed to coronary
artery disease in 34 patients and to a cardiomyopathy in 16
patients. During exercise, all patients were limited by
dyspnea or fatigue; no patient was limited by angina or
intermittent claudication. Ten patients were New York
Heart Association functional class II, 37 were class III and
3 were class IV.
Protocol. As part of clinical care, patients routinely un-
dergo cardiopulmonary exercise testing on initial evaluation
by the Vanderbilt Heart Failure Program. Exercise testing is
then repeated three to six months after initial evaluation and
annually thereafter. Additional testing is performed if the
patient reports major changes in exertional symptoms.
Exertional symptoms are recorded at each visit by quan-
tifying the level of fatigue and dyspnea from 0 to 3 (0 5
none; 1 5 mild; 2 5 moderate; 3 5 severe). A composite
symptom score was determined by adding the fatigue and
dyspnea scores.
For the present study, all maximal exercise tests and
symptom assessments performed on the patients were ana-
lyzed. Patients performed an average of 3.7 exercise tests at
average intervals of 4.3 months. Exercise tests were excluded
from analysis if the respiratory gas exchange ratio did not
exceed 1.0 at peak exercise, a finding that suggests an
inadequate patient effort (2,5).
Maximal exercise testing was performed using a 3-min
Naughton protocol and a Marquette treadmill (Milwaukee,
Wisconsin). During exercise, patients were connected to a
CardioO2 System (MedGraphics, Minneapolis, Minne-
sota) via a disposable pneumotach. The patient was also
attached to a Pulse Oximeter via a device on the finger to
noninvasively measure arterial oxygen saturation. Exercise
loads were increased every 3 min. The electrocardiogram
and heart rate were monitored continuously. Arterial blood
pressure was measured at rest and every 3 min during
exercise using a cuff sphygmomanometer.
Peak exercise minute oxygen consumption (VO2) was
defined as the maximal oxygen consumption level noted
during exercise and was expressed as ml/min/kg body
weight. The anaerobic threshold was defined using three
criteria: the point after which the respiratory gas exchange
ratio (minute carbon dioxide consumption [VCO2]/CO2)
consistently exceeded the resting ratio, the point at which
the ventilatory equivalent for oxygen (minute ventilation
[VE]/VO2) was minimal followed by a progressive increase
in VE/VO2 and the VO2 after which a nonlinear rise in VE
occurred relative to VO2 (2,6,7). When these three criteria
identified different anaerobic thresholds, results of the
different threshold were averaged. The anaerobic threshold
was expressed as ml/min/kg of oxygen uptake.
During the course of the study, most patients exhibited
improvements in symptoms and peak exercise VO2. These
improvements were primarily related to adjustments in
medications, particularly diuretic doses, and to efforts to
increase patient activity levels.
Data analysis. All data are expressed as mean 6 standard
deviation. Correlations between variables were assessed
using least square regression analysis. Comparison between
group data was performed using Student paired or unpaired
t testing, as appropriate. A p value , 0.05 was considered
statistically significant.
RESULTS
The 50 study patients underwent a total of 185 cardiopul-
monary tests at an average interval of 4.3 months (average
tests/patient 5 3.7). At baseline exercise testing, peak
exercise VO2 averaged 14.7 6 4.7, the anaerobic threshold
averaged 11.2 6 1.9 ml/min/kg and composite symptom
scores averaged 2.9 6 1.8. During the study period, peak
exercise VO2 improved to 16.1 6 4.3 (p , 0.02 vs.
baseline), whereas symptom scores improved to 1.4 6 1.8
(p , 0.01 vs. baseline).
Composite symptom scores correlated significantly with
peak exercise VO2 both at the time of baseline exercise
testing (r 5 0.45) and throughout the study period (r 5
0.47) (both p , 0.001) (Figs. 1 and 2). Composite symptom
scores also correlated significantly with peak exercise minute
ventilation (r 5 0.24), peak VCO2/kg (r 5 0.47), the ratio
of peak minute ventilation to peak VCO2 (r 5 0.48) and the
anaerobic threshold (r 5 0.378) (all p , 0.001). There was
no significant correlation between composite symptom score
and the peak exercise respiratory gas exchange ratio.
Changes in symptom scores from the baseline to final
exercise test correlated significantly with changes in peak
exercise VO2 (r 5 0.50, p , 0.01) (Fig. 3). Regression
equations suggested that exertional symptoms on average
developed when peak VO2 decreased below 18 ml/min/kg,
Abbreviations and Acronyms
VE 5 minute ventilation
VO2 5 minute oxygen consumption
VCO2 5 minute carbon dioxide production
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with a decrease in peak VO2 of 1 ml/min/kg being associ-
ated with an increase in symptom score of approximately 1.
However, symptom scores often underestimated the se-
verity of functional disability (Fig. 4). Peak exercise VO2
was ,14 ml/min/kg, consistent with severe functional
limitation, during 65 exercise tests. During these tests,
patients reported minimal or no clinical symptoms (com-
posite scores #2) 45% of the time. Peak exercise VO2 was
14–18 ml/min/kg, consistent with moderate functional
limitation, during 74 exercise tests. At the time of these
tests, 72% of the patients reported minimal or no clinical
symptoms. Peak exercise VO2 was .18 ml/min/kg during
54 tests. At the time of these tests, 87% of patients reported
minimal or no clinical symptoms. The anaerobic threshold
occurred at a similar percentage of peak exercise VO2 in
patients reporting minimal or no clinical symptoms (73 6
12%) versus patients with composite scores .2 (74 6 13%)
(p 5 NS).
Symptom changes noted in individual patients over the
study also tended to correlate poorly with changes in
functional capacity. When individual changes in peak exer-
cise VO2 were examined, 18 patients exhibited a .20%
increase in peak VO2 (11.3 6 3.6 to 17.2 6 4.7 ml/min/kg),
while 8 patients had a .20% decrease in peak VO2 (18.2 6
2.6 to 12.9 6 2.4 ml/min/kg) (both p , 0.01). On average,
patients with a .20% increase in peak VO2 had a highly
significant improvement in symptom score, from 3.3 6 1.9
to 1.2 6 1.8 (p , 0.0001). However, eight of the patients
exhibited minimal or no changes in symptom score (change
in symptom score 5 0–1). Patients with a .20% decrease
in peak VO2 actually had no significant change in symptom
score (2.8 6 1.5 to 3.1 6 2.0).
Coronary artery disease versus cardiomyopathy. To de-
termine if the relationship between symptoms and peak
VO2 differed in the patients with coronary artery disease
versus those with a cardiomyopathy, analysis was performed
on these two subgroups. At baseline, both groups had
similar symptom levels (coronary disease: 2.7 6 1.7 vs.
cardiomyopathy: 3.0 6 1.9) and peak VO2 (coronary
disease: 15.2 6 4.7 vs. 14.1 6 4.6 ml/min/kg) (both p 5
NS). During the course of the study, patients with coronary
disease exhibited significantly less change in peak VO2
when compared with patients with a cardiomyopathy (0.2 6
3.3 vs. 2.9 6 5.4 ml/min/kg [p , 0.04]) but exhibited
similar changes in symptom scores (21.4 6 1.7 vs. 1.5 6
2.3 [p 5 NS]).
Figure 1. Relationship between baseline peak exercise VO2 and
composite symptom scores (n 5 50).
Figure 2. Relationship between baseline peak exercise VO2 and
composite symptom scores over the entire study period (n 5 185).
Figure 3. Relationship between changes in peak exercise VO2 and
changes in composite symptom scores between the baseline and
final exercise test.
Figure 4. Symptom scores associated with peak exercise VO2
levels of ,14 (n 5 65), 14–18 (n 5 74) and .18 (n 5 54)
ml/min/kg.
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DISCUSSION
Over the past decade, exercise testing has been used widely
in research studies to assess the functional capacity of
patients with heart failure and to evaluate the effect of
therapeutic interventions (1–3,5). In contrast, exercise test-
ing is rarely used by clinicians managing patients with heart
failure. Instead, clinicians rely almost exclusively on the
clinical history to assess the functional capacity of patients
with heart failure and to track responses to therapy.
This approach is based on the assumption that the
symptoms reported by a patient with heart failure are related
to the patient’s functional ability. This assumption may
appear intuitively correct. However, the symptoms reported
by a patient potentially could have little or no relationship to
functional capacity. Functional capacity is a measure of a
person’s ability to perform work. In contrast, the exertional
symptoms reported by a patient reflects the patient’s sub-
jective response to activities actually performed and there-
fore will be influenced by the intensity of activities under-
taken and by psychological factors.
The present study was undertaken to investigate the
relationship between symptom levels reported by patients
with heart failure and an objective index of exercise capacity:
peak exercise VO2. To assess exertional symptoms, exer-
tional dyspnea and fatigue were each scored separately and
then added together to obtain a composite score. Peak
exercise VO2 was used to objectively assess maximal exercise
capacity based on extensive data, suggesting that this index
provides the most accurate and reproducible index of peak
exercise capacity available (2,5). Exercise tests were included
in the analysis only if the respiratory gas exchange ratio, the
ratio of VCO2 to VO2, exceeded 1.0 at peak exercise,
suggesting adequate patient effort (2,5).
Results of this study indicate that there is a definite
relationship between symptoms reported by patients and
functional capacity. Symptom scores compiled at the base-
line exercise test correlated with peak exercise VO2 (Fig. 1).
A similar correlation was observed when results from all 185
exercise tests were compared with symptom scores (Fig. 2).
Changes in symptom score over the study period also
correlated with changes in peak exercise VO2 (Fig. 3).
The correlations noted between peak exercise VO2 and
symptom scores indicated that exertional symptoms were on
average minimal or absent when the peak exercise VO2
achieved a level of approximately 18 ml/min/kg. A decrease
in VO2 of 1 ml/min/kg below this level was associated with
an increase in symptom score of approximately 1. Therefore,
one would predict severe symptoms (composite symptom
score 5 6) at a peak VO2 level of approximately 12. This
finding is consistent with prior observations. Weber et al.
considered a peak VO2 .20 ml/min/kg to be associated
with a relatively asymptomatic state, and a peak VO2 ,10
to be associated with severe functional limitation (2). Solal
and Gourgon noted that most patients with few exertional
symptoms had a peak VO2 level .18 ml/min/kg, and that
patients with severe exercise limitation had an average peak
VO2 level of 12 ml/min/kg (5).
Such observations suggest that exertional symptoms par-
allel functional capacity to some extent. However, the
degree of correlation between symptoms and peak exercise
VO2 noted in this study was extremely weak. For any given
symptom level, patients exhibited widely varying levels of
peak exercise VO2. Of particular note, symptom scores
tended to underestimate the level of functional disability.
Patients who had peak exercise VO2 levels ,14 ml/min/kg,
consistent with moderate to severe functional disability,
reported minimal or no symptoms 45% of the time. When
peak exercise levels were between 14 and 18 ml/min/kg,
consistent with mild to moderate functional disability,
patients reported minimal or no symptoms 72% of the time.
The relationship between respiratory gas data and symp-
toms was not improved by substituting the anaerobic
threshold, peak exercise ventilation or the ratio of minute
ventilation to carbon dixoide production for peak exercise
VO2.
Changes in symptoms over time also did not track closely
with changes in functional capacity. Although patients who
exhibited a .20% increase in peak exercise VO2 during the
study exhibited a highly significant improvement in symp-
toms as a group, 44% of these patients reported minimal or
no change in symptom scores. Even a larger percentage of
patients who exhibited a .20% decrease in peak VO2
reported minimal or no change in symptom scores.
These observations strongly suggest that clinical symp-
toms do not provide a reliable index of functional capacity in
heart failure. In particular, reliance on clinical symptoms is
likely to underestimate the extent of functional disability
experienced by patients, because many functionally disabled
patients appear to report few if any clinical symptoms.
Why try to identify patients with reduced functional
capacity if they report few exertional symptoms? It is very
likely that such patients are functionally limited during
normal daily activities, but have altered their lifestyle to
adapt to their disability. Such patients should be made
aware of their disability and efforts made to improve their
functional capacity. Many of these patients are probably
deconditioned and may improve with an exercise program
(8–10). Some patients may have associated lung dysfunction
and benefit from bronchodilators. Other patients may have
unsuspected fluid retention and benefit from additional
diuresis (11). Still other patients may benefit from medica-
tion adjustments.
This management strategy is likely to substantially im-
prove the overall functional ability of patients with heart
failure. In addition, correcting functional disability may
potentially improve prognosis. A number of groups have
demonstrated that peak exercise VO2 correlates with sur-
vival in heart failure, suggesting that exercise capacity
influences prognosis, possibly via an impact on neuro-
homones (12–14). Stevenson et al. (15) have also demon-
strated that improvements in peak exercise VO2 are associ-
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ated with improved clinical stability and with fewer
hospitalizations. However, it should be emphasized that this
study did not address the impact of therapies on functional
capacity. Further studies are needed to determine if cardio-
pulmonary exercise testing can be used to guide therapeutic
interventions.
In summary, results of this study suggest that the clinical
history does not provide a reliable method of detecting and
monitoring functional capacity in heart failure. Formal
exercise testing should be used more frequently in this
population to identify patients with substantial functional
disability.
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